aceneuramic acid
Small moleculeexperimental
N-Acetylneuraminic acid is the predominant sialic acid found in human cells, and many mammalian cells. Other forms, such as N-Glycolylneuraminic acid, may also occur in cells. — Wikipedia
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Nov 1, 2010 (NCT01236898)
Timeline
Indications
Mechanism of action
- Sialic acid-binding Ig-like lectin 11Supplementation
SIGLEC11 supplementation
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N[C@@H]([C@@H](O)[C@H](O)[C@H](O)CO)[C@@H](O)CC(=O)C(=O)O- Mol. weight
- 309.27 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaN-Acetylneuraminic acid ↗
- ChEMBLCHEMBL2105945 ↗
Also known as
- aceneuramic acid
- aceneuramic acid
- aceneuramic acid
- ux-001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04671472 | Phase 3 | Feb 8, 2021 | Nobel Pharmaceuticals |
| NCT02731690 | Phase 2 | Jun 1, 2016 | Ultragenyx Inc. |
| NCT02736188 | Phase 3 | Apr 1, 2016 | Ultragenyx Inc. |
| NCT01236898 | Phase 1 | Nov 1, 2010 | Tohoku University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ultragenyx Inc. | For profit | 2 | 2 | 2 | 2016 |
| Nobel Pharmaceuticals | For profit | 1 | 1 | 1 | 2021 |
| Tohoku University | Academic/Hospital | 1 | 1 | 1 | 2010 |
3 organizations
Page 1 / 1